$5.2 billion purchase! Pfizer Boro ointment is about to be approved in China for the treatment of special dermatitis.

On July 24th Pfizer filed an application in China for the listing of creboro ointment, a new drug for special dermatitis, which entered the administrative approval stage and is expected to be approved in the near future.
dermatitis, commonly referred to as eczema, is a chronic recurrent skin disease, mainly manifested in severe itching, eczema-like damage and dry skin, good in children, most of the onset of inflammation.
According to statistics, about 10 per cent of adults and 20 per cent of children worldwide are affected by endexual dermatitis, 45 per cent of cases occur six months ago, 60 per cent of cases occur before the age of one, 85 per cent of cases occur before the age of five, and about 50 per cent of children repeat them during adolescence and adulthood.
Creboro, a nonsteroidal PDE4 inhibitor developed by Anacor, was acquired by Pfizer in May 2016 for $5.2 billion, and in December of that year, Kryboro was approved by the FDA for listing as the first prescription drug for specialty dermatitis and the first non-steroidal drug to inhibit skin PDE4 in 10 years.
2019, Eucrisa had sales of $138 million.
Ointment has previously been included in the "second batch of clinically urgent need for new drugs abroad" list in China.
Pfizer submitted its application for the drug to market in China in February 2020.
.